Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-based therapies for prostate cancer.
McNeel DG, Malkovsky M. McNeel DG, et al. Immunol Lett. 2005 Jan 15;96(1):3-9. doi: 10.1016/j.imlet.2004.06.009. Immunol Lett. 2005. PMID: 15585302 Review.
Newer therapies in advanced prostate cancer.
Hegeman RB, Liu G, Wilding G, McNeel DG. Hegeman RB, et al. Among authors: mcneel dg. Clin Prostate Cancer. 2004 Dec;3(3):150-6. doi: 10.3816/cgc.2004.n.025. Clin Prostate Cancer. 2004. PMID: 15636681 Review.
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G. McNeel DG, et al. Clin Cancer Res. 2005 Nov 1;11(21):7851-60. doi: 10.1158/1078-0432.CCR-05-0262. Clin Cancer Res. 2005. PMID: 16278408 Clinical Trial.
Cellular immunotherapies for prostate cancer.
McNeel DG. McNeel DG. Biomed Pharmacother. 2007 Jul;61(6):315-22. doi: 10.1016/j.biopha.2006.12.006. Epub 2007 Jan 26. Biomed Pharmacother. 2007. PMID: 17306498 Review.
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Agus DB, et al. Among authors: mcneel dg. J Clin Oncol. 2007 Feb 20;25(6):675-81. doi: 10.1200/JCO.2006.07.0649. J Clin Oncol. 2007. PMID: 17308272 Clinical Trial.
139 results